Reports Q2 revenue $892,000, consensus $6.44M. “We are entering the second half of the year with momentum across both our commercial and clinical programs,” said Samarth Kulkarni, chairman and CEO of Crispr Therapeutics (CRSP). “The activation of 75 authorized treatment centers for CASGEVY has been achieved, marking a meaningful step in expanding patient access, while clinical trials across multiple other programs continue to advance. Looking ahead, we expect several key milestones including the presentation of complete Phase 1 data for CTX310, as well as updates across our oncology and autoimmune portfolios. Our focus remains on delivering transformative therapies for patients with critical unmet needs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Cathie Wood Buys $69M Worth of Figma Stock on Blockbuster IPO Debut
- CRSP, ABSI, IRDM: Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Buys Absci and Iridium
- Insiders Are Betting Big on These 2 Stocks – Should You Follow Their Lead?
- Crispr Therapeutics price target lowered to $78 from $79 at BofA
- CRISPR Stock (CRSP) Continues to Sizzle on Insider Deal